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1 |  INTRODUCTION
Type 2 diabetes has traditionally been viewed as a progres-
sive, irreversible condition; however, remission is high on the 
agenda of people with diabetes,1 and the concept is increas-
ingly recognized within clinical guidelines.2 We showed within 
a primary care-based randomized controlled trial that a large 
proportion of people living with type 2 diabetes can achieve 
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Abstract
Aim: To identify predictors of type 2 diabetes remission in the intervention arm of 
DiRECT (Diabetes Remission Clinical Trial).
Methods: Participants were aged 20–65 years, with type 2 diabetes duration of <6 years 
and BMI 27–45 kg/m2, and were not receiving insulin. Weight loss was initiated by total 
diet replacement (825–853 kcal/day, 3–5 months, shakes/soups), and weight loss main-
tenance support was provided for 2 years. Remissions (HbA1c <48 mmol/mol [<6.5%], 
without antidiabetes medications) in the intervention group (n = 149, mean age 53 years, 
BMI 35 kg/m2) were achieved by 68/149 participants (46%) at 12 months and by 53/149 
participants (36%) at 24 months. Potential predictors were examined by logistic regres-
sion analyses, with adjustments for weight loss and effects independent of weight loss.
Results: Baseline predictors of remission at 12 and 24 months included being prescribed 
fewer antidiabetes medications, having lower triglyceride and gamma-glutamyl trans-
ferase levels, and reporting better quality of life with less anxiety/depression. Lower 
baseline HbA1c was a predictor at 12 months, and older age and male sex were predictors 
at 24 months. Being prescribed antidepressants predicted non-remission. Some, but not 
all effects were explained by weight loss. Weight loss was the strongest predictor of re-
mission at 12 months (adjusted odds ratio per kg weight loss 1.24, 95% CI 1.14, 1.34; P < 
0.0001) and 24 months (adjusted odds ratio 1.23, 95% CI 1.13, 1.35; P <0.0001). Weight 
loss in kilograms and percentage weight loss were equally good predictors. Early weight 
loss and higher programme attendance predicted more remissions. Baseline BMI, fasting 
insulin, fasting C-peptide and diabetes duration did not predict remission.
Conclusions: Other than weight loss, most predictors were modest, and not sufficient 
to identify subgroups for which remission was not a worthwhile target.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
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sustained remissions if they lose sufficient weight within 6 
years of diagnosis.3,4 Potentially life-changing remissions were 
clearly related to degree of weight loss, at 1 year reaching 73% 
with ≥10-kg loss, and 86% with ≥15-kg loss. Intensive weight 
management programmes place new demands on people seek-
ing remission and on healthcare services, so there could be 
value in identifying individuals or subgroups who are more 
likely to achieve remission, or for whom weight loss is likely 
to be unsuccessful. However, little published evidence allows 
prediction of diabetes remission following diet-induced weight 
loss. We have therefore conducted a post hoc analysis of demo-
graphic and clinical data in the DiRECT (Diabetes Remission 
Clinical Trial) database to investigate whether it is possible at 
baseline or early in treatment to predict which people are more 
or less likely to achieve remission, with reference to factors also 
predicting weight loss.
2 |  METHODS
DiRECT is a cluster-randomized, clinical trial, conducted 
within routine primary care practice. The study protocol,5 
recruitment and baseline data6 and primary outcome re-
sults have all been published.3,4 The trial was registered at 
Controlled Trials, www.contr olled -trials.com/ISRCT N0326 
7836. Practices agreeing to participate were randomized to 
intervention or control arms, which proved well balanced at 
baseline with regard to demographic and clinical factors.6 
The main inclusion criteria were type 2 diabetes, diagnosed 
using WHO criteria, within 6 years, with most recent HbA1c 
≥48 mmol/mol [≤6.5%; or ≥43 mmol/mol (≤6.1%) if on an-
tidiabetes medication], age 20–65 years and BMI 27–45 kg/
m2. Given that weight loss is assumed to be the main de-
terminant of remission, our analyses were restricted to the 
intervention group in DiRECT, although a few controls did 
achieve remission (n = 6 at 12 months, n = 5 at 24 months).
The intervention was an evidence-based weight manage-
ment programme,7 delivered in participants’ own general 
practice by a nurse or local dietitian. Briefly, weight loss was 
initiated by 12–20 weeks of total diet replacement (825–853 
kcal/day, shakes/soups) and fortnightly study visits, followed 
by food reintroduction, and monthly support for long-term 
weight loss maintenance up to 2 years. All oral antidiabe-
tes and anti-hypertensive drugs were discontinued on com-
mencing the weight management programme. Blood glucose 
and blood pressure were monitored at each appointment, and 
medications were reintroduced if indicated.
2.1 | Outcomes
Baseline variables and weight losses during the intervention 
period were examined as potential predictors of remission 
at 12 and 24 months in the intervention group (n = 149, 
mean age 53 years, BMI 35 kg/m2). Remission was defined 
as HbA1c <48 mmol/mol (<6.5%), after at least 2 months 
without glucose-lowering medications, in line with criteria 
adopted by UK diabetes organizations.8,9 Predictor variables 
were selected based on available data within the DiRECT 
database. Data were collected at baseline, 12 and 24 months, 
or from general practice records (if available within a win-
dow of ±100 days), as prespecified in the protocol for par-
ticipants who ceased to engage and did not attend their 12 
and 24 month trial appointment.5 For those participants who 
did not attend the 12 and 24 month study assessments, and 
for whom data could not be obtained from general practice 
records, we made the assumption that remission was not 
achieved. Weight change data were available for 137 par-
ticipants at 12 months, and 129 participants at 24 months.
2.2 | Statistical analysis
Continuous variables are summarized as mean and standard 
deviation, as all were deemed sufficiently normally distrib-
uted. Categorical variables are summarized as number and 
percentage per category. To assess the effect of baseline 
characteristics on remission, mixed effects logistic regression 
was used. It is assumed that the main effect of the interven-
tion is weight loss. We also examined whether factors other 
than weight loss may be predictors of remission. In trying to 
separate these effects we analysed the relation of weight loss 
What's new?
• With ≥10 kg weight loss, 64% of early type 2 dia-
betes is reversible, but few data are available on 
factors predicting diabetes remission following 
diet-induced weight loss.
• Other than weight loss, most predictors were mod-
est overall and, re-assuringly, none was sufficient 
to identify people for whom remission is not a 
worthwhile target.
• Remission was more likely for men, as a result 
of larger weight losses, and for those prescribed 
fewer antidiabetes medications at baseline. 
Remission was less likely for people with anxi-
ety or depression, mainly due to smaller weight 
losses.
• Remission is a realistic aspiration for most people 
with type 2 diabetes diagnosed within 6 years, and 
achieving ≥10 kg weight loss should be a primary 
target of routine diabetes care at diagnosis, and 
before the escalation of therapy.
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T A B L E  1  Baseline characteristics of the intervention group, by remission status at 12 and 24 months
All (n=149)
No remission at 12 
months or 24 months 
(n=76)
Remission at 12 
months but not 24 
months (n=20)
Remission at 24 
months (n=53)
Age, years 52.9 (7.6) 51.5 (7.8) 51.2 (7.7) 55.6 (6.6)
Men, n (%) 83 (56) 39 (51) 7 (35) 37 (70)
Women, n (%) 66 (44) 37 (49) 13 (65) 16 (30)
IMD, n (%)
Quintile 1 – most deprived 31 (21) 19 (25) 4 (24) 8 (15)
Quintile 2 24 (16) 14 (18) 3 (18) 7 (13)
Quintile 3 38 (26) 23 (30) 4 (24) 11 (21)
Quintile 4 29 (20) 10 (13) 5 (29) 14 (26)
Quintile 5 – least deprived 24 (16) 10 (13) 1 (6) 13 (25)
Diabetes duration, years 3.0 (1.7) 3.1 (1.8) 3.0 (1.8) 3.0 (1.5)
Weight, kg 101.0 (16.7) 101.1 (17.5) 101.1 (18.5) 100.9 (15.1)
BMI, kg/m2 35.1 (4.5) 34.9 (4.6) 36.6 (3.7) 34.8 (4.7)
Systolic blood pressure, mmHg 132.7 (17.5) 129.5 (16.1) 134.4 (20.5) 136.6 (17.6)
EQ-5D health utility score 0.8 (0.3) 0.7 (0.3) 0.9 (0.1) 0.9 (0.2)
EQ-5D Mobility, number with problems (%) 40 (27) 27 (36) 4 (20) 9 (17)
EQ-5D Selfcare, number with problems (%) 14 (9) 10 (13) 1 (5) 3 (6)
EQ-5D Activities, number with problems (%) 34 (23) 23 (30) 4 (20) 7 (13)
EQ-5D Pain, number with problems (%) 63 (42) 40 (53) 7 (35) 16 (30)
EQ-5D Anxiety and depression, number with 
problems (%)
37 (25) 28 (37) 6 (30) 3 (6)
EQ-5D 100-point visual analogue scale 65.8 (19.1) 62.9 (19.6) 57.4 (13.8) 73.1 (18.1)
HbA1c, mmol/mol 60.4 (13.7) 63.4 (14.6) 58.2 (15.0) 57.0 (10.7)
HbA1c, % 7.7 (1.3) 8.0 (1.3) 7.5 (1.4) 7.4 (1.0)
Insulin, µUml 24.5 (15.0) 23.9 (14.1) 25.7 (12.4) 25.1 (17.0)
C-peptide, ng/ml 5.4 (2.4) 5.6 (2.4) 5.7 (2.2) 5.2 (2.5)
Gamma-glutamyl transferase, u/l 50.2 (51.0) 56.0 (65.8) 48.4 (25.1) 42.4 (28.3)
Triglycerides, mmol/l 2.1 (1.4) 2.2 (1.4) 1.6 (0.6) 2.0 (1.5)
Number of antidiabetes medications 1.1 (0.9) 1.5 (1.0) 0.9 (0.8) 0.8 (0.7)
Not prescribed metformin or gliclazide, n (%) 38 (26) 12 (16) 6 (30) 20 (38)
Metformin only, n (%) 75 (50) 37 (49) 12 (60) 26 (49)
Gliclazide only, n (%) 8 (5) 5 (6) 0 (0) 3 (6)
Metformin and gliclazide, n (%) 28 (19) 22 (29) 2 (10) 4 (8)
Number of anti-hypertensive medications 1.0 (1.2) 0.9 (1.1) 1.1 (1.0) 1.2 (1.2)
Prescribed antidepressants, n (%)
No 109 (73) 49 (65) 12 (60) 48 (91)
Yes 40 (27) 27 (35) 8 (40) 5 (9)
Binge eating score (min. = 0, max. = 4) 1.3 (1.3) 1.4 (1.5) 1.5 (1.3) 1.2 (1.2)
Note: Data are presented as mean± sd, unless otherwise stated.
IMD was assessed according to study participant postcode, binge eating scores were determined using a simple screening questionnaire 30 and quality of life was 
measured by the EQ-5D.
Abbreviations: EQ-5D, EuroQol five-dimension questionnaire; IMD, Index of Multiple Deprivation.
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to remission using a mixed effects logistic regression model 
predicting remission from weight loss. The residuals of this 
model represent the part of the remission information that is 
not explained by weight loss. In the next step, for each base-
line characteristic, we have fitted a linear mixed effects re-
gression model predicting the residuals from the first model, 
i.e. the part of remission that is not explained by weight loss. 
In addition, for each baseline characteristic, we fitted a lin-
ear mixed effects regression model predicting weight loss 
from the baseline characteristic. All analysis models were 
adjusted for the stratification variables used in the randomi-
zation [study centre (Scotland or Tyneside), practice list size 
(≤5700, >5700)] and a random effect for practice. Statistical 
analyses were carried out in R for Windows, version 3.2.4. 
A 5% α-level was used throughout, with no adjustment for 
multiplicity of statistical tests.
2.3 | Ethics
Ethical approval was granted from the West of Scotland 
Research Ethics Committee (reference number: 13/WS/0314) 
and all participants provided written informed consent.
3 |  RESULTS
Baseline characteristics have been reported previously3,4,6 
and additional details for the 149 participants in the interven-
tion arm are shown in Table 1. The study drop-out rate was 
low, and predictors of diabetes remission were derived using 
available data from 142/149 participants (95%) at 12 months, 
and 129/149 participants (87%) at 24 months.
3.1 | Predictors of type 2 diabetes remission 
at 12 and 24 months
Remission of type 2 diabetes was achieved by 46% (n=68/149) of 
participants at 12 months, and by 36% (n=53/149) at 24 months.
3.1.1 | Baseline predictors of remission
Single and multivariate model predictors of remission are 
shown in Figures 1 and 2, with the effect of weight loss 
and effects independent of weight loss for each predictor 
variable also shown (please also see Tables S1–S4 in the 
F I G U R E  1  a) Predictions of remission at 12 months from baseline characteristics and from weight losses and attendance; b) Predictions of 
remission at 12 months: the estimated effect of weight loss; c) Predictions of remission at 12 months: effects independent of weight loss. The IMD 
reference is quintile 5 (i.e. the odds ratios shown are in relation to quintile 5)
Age (per 1 year)
Sex (female vs male)
IMD
Duration of diabetes (per 1 year)
SBP (per 10 mmHg)
HbA1c (per 5 mmol/mol)
HbA1c (per 1 %)
Insulin (per 10 uu/ml)
Triglycerides (per 1 mmol / l)
Gamma−glutamyl transferase (per 10 u/l)
C−peptide (per 1 ng/ml)
No. of antidiabetes medications (per 1 medication)
Metformin and
Gliclazide
No. of antihypertensives (per 1 medication)
Antidepressants
EQ−5D 100−point VAS (per 10 points)





EQ−5D anxiety and depression*
Binge eating score (per 1 point)
Weight loss at week 4 (per 1 kg)
Weight loss at week 4 (per 1 %)
Weight loss at week 8 (per 1 kg)
Weight loss at week 8 (per 1 %)
No. of treatment visits up to week 8 (per 1 visit)
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supplementary file accompanying this manuscript for ad-
ditional remission predictor data). Being prescribed fewer 
antidiabetes medications was the strongest predictor at 12 
and 24 months (P<0.001), an effect confirmed by mul-
tivariate analysis, and odds of remission were lowest for 
those prescribed sulfonylureas and metformin. Participants 
with higher HbA1c were less likely to achieve remission at 
12 months (adjusted odds ratio per 1 mmol/mol: 0.96 [95% 
CI: 0.93, 0.99], P=0.017; adjusted odds ratio per 1%: 0.66 
[95% CI: 0.47, 0.93], P=0.018], although effects were at-
tenuated by 24 months (adjusted odds ratio per 1 mmol/mol: 
0.97 [95% CI: 0.94, 1.00], P=0.062; adjusted odds ratio per 
1%: 0.71 [95% CI: 0.50, 1.02], P=0.062). Odds of remission 
were also lower at 12 and 24 months for participants with 
higher triglyceride and gamma-glutamyl transferase (GGT) 
concentrations, and GGT was a predictor in the 24-month 
multivariate model (adjusted odds ratio per 1 u/l, 0.99 [95% 
CI: 0.97, 1.00]; P=0.022). Higher systolic blood pressure 
was a predictor of remission at 12 and 24 months (single and 
multivariate models) and increasing age predicted remission 
at 24 months only.
Better quality of life (as measured by the EuroQol five-di-
mension questionnaire [EQ-5D] score) and no problems 
with pain were predictors of remission across the study and 
neither were explained by weight loss effects, whereas higher 
levels of anxiety/depression and antidepressant usage pre-
dicted non-remission, largely due to smaller weight losses. 
Deprivation category (Index of Multiple Deprivation), when 
considered as a whole, influenced remission (12 months: 
P=0.020 [multivariate model only]; 24 months: P=0.049 
[single predictor model only]), although statistical differ-
ences between subgroups were not observed. Quality-of-life 
scores were higher for people in more affluent groups (P = 
0.004). Deprivation did not explain anti-depressant usage (P 
= 0.946).
There was no statistically significant sex effect on remis-
sion at 12 months, but remissions were more durable in men, 
with significant differences evident at 24 months, effects 
which were explained by greater absolute weight loss. Men 
had greater weight losses than women at 12 months (11.7 ± 
7.8 kg/11.0 ± 6.7% vs 7.8 ± 7.8 kg/8.4 ± 5.6%; P=0.004 [kg], 
P=0.067 [%]) and 24 months (8.9 ± 6.3 kg/8.5 ± 8.4% vs 
6.0 ± 6.4 kg/6.6 ± 7.0%; P=0.012 [kg], P=0.136 [%]). Being 
prescribed antidepressants was associated with significantly 
less weight loss throughout the study, and was a predictor of 
non-remission at 24 months. Fasting insulin, fasting C-peptide 
and duration of diabetes were not predictors of remission at 
either time point.
Age (per 1 year)
Sex (female vs male)
IMD
Duration of diabetes (per 1 year)
SBP (per 10 mmHg)
HbA1c (per 5 mmol/mol)
HbA1c (per 1 %)
Insulin (per 10 uu/ml)
Triglycerides (per 1 mmol / l)
Gamma−glutamyl transferase (per 10 u/l)
C−peptide (per 1 ng/ml)
No. of antidiabetes medications (per 1 medication)
Metformin and
Gliclazide
No. of antihypertensives (per 1 medication)
Antidepressants
EQ−5D 100−point VAS (per 10 points)





EQ−5D anxiety and depression*
Binge eating score (per 1 point)
Weight loss at week 4 (per 1 kg)
Weight loss at week 4 (per 1 %)
Weight loss at week 8 (per 1 kg)
Weight loss at week 8 (per 1 %)
No. of treatment visits up to week 8 (per 1 visit)
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3.1.2 | Programme-related 
predictors of remission
Figure 3 shows remission rates by weight loss category from 
baseline in intervention group participants. Weight loss was 
the strongest predictor of remission at 12 and 24 months, 
irrespective of baseline BMI, with absolute (kg) and per-
centage (%) weight loss equally good predictors. Numbers 
of remissions increased in a stepwise manner with weight 
loss (Figure 3). Weight losses achieved as early as 4 weeks 
were significant predictors of remission at 12 and 24 months, 
and higher programme attendance was also associated with 
achieving remission. Of the 68 participants achieving initial 
remission at 12 months, 29% (20/68) relapsed and diabetes 
re-occurred at 24 months. Average weight regain was 7.1 ± 
5.4 kg in relapsers compared to 4.2 ± 3.7 kg in those main-
taining remission (P=0.073).
3.1.3 | Protocol for early 
stopping of treatment
At 8 weeks, 28 participants (19%) had failed to achieve 6 
kg weight loss, but six of the 28 did not start the total diet 
replacement intervention after enrolment. Of the remaining 
22 participants, 11 withdrew from treatment before the end 
of the total diet replacement phase and six participants went 
on to achieve remission (89% sensitivity, 23% specificity for 
predicting remission at 24 months).
4 |  DISCUSSION
An ability to predict treatment success, or failure, from base-
line information might be of value to manage the expectations 
of people who currently have type 2 diabetes, and clinicians, 
and also to guide resource management. In this post hoc anal-
ysis of the DiRECT trial, we found several baseline measures 
which were statistical predictors of remission, some of which 
were not explained by differences in weight loss; however, 
predictive power was modest at best, and in practice none 
were sufficient to identify people for whom remission was 
not a worthwhile goal. Remission should therefore be consid-
ered a realistic management target for any individual within 
6 years of diagnosis. It can be achieved safely and effectively 
using evidence-based weight management,10,11 and most in-
dividuals will achieve remission with ≥10 kg/% weight loss, 
although ≥15kg/% provides greater assurance.
Age (per 1 year)
Sex (female vs male)
IMD
Duration of diabetes (per 1 year)
SBP (per 10 mmHg)
HbA1c (per 5 mmol/mol)
HbA1c (per 1 %)
Insulin (per 10 uu/ml)
Triglycerides (per 1 mmol / l)
Gamma−glutamyl transferase (per 10 u/l)
C−peptide (per 1 ng/ml)
No. of antidiabetes medications (per 1 medication)
Metformin and
Gliclazide
No. of antihypertensives (per 1 medication)
Antidepressants
EQ−5D 100−point VAS (per 10 points)





EQ−5D anxiety and depression*
Binge eating score (per 1 point)
Weight loss at week 4 (per 1 kg)
Weight loss at week 4 (per 1 %)
Weight loss at week 8 (per 1 kg)
Weight loss at week 8 (per 1 %)
No. of treatment visits up to week 8 (per 1 visit)
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This paper attempts to answer some of the most common 
practical questions being asked by clinicians and healthcare 
planners regarding likelihood of remission, and was therefore 
restricted to examining possible predictors of practical clini-
cal value, rather than addressing mechanistic predictors. The 
strongest baseline predictor of remission related to antidiabe-
tes medications prescribed, with greater likelihood of remis-
sion when weight loss is achieved prior to the introduction of 
first or second-line oral hypoglycaemic agents. Reverse cau-
sality is possible, since being prescribed more medications 
is likely to be a marker of disease progression and declining 
β-cell function, obstructing remission. After diagnosis, the 
step between intensifying antidiabetes drug therapy, from one 
agent to two, represents an important signal that the opportu-
nity for remission is diminishing. We identified several pre-
dictors of remission, and effect sizes for many of these appear 
reasonably strong, but confidence intervals are fairly wide, 
suggesting the precision and certainty of these estimates are 
too weak to have reliable clinical relevance, or to justify in-
fluence over policy or resource allocation. Re-assuringly, re-
missions remained frequent across these variables, and some 
predictors (e.g. male sex, less anxiety/depression) were ex-
plained by greater weight loss. Although not all people with 
type 2 diabetes are able to achieve remission, limiting this 
type of service to those most likely to be successful cannot be 
done using the criteria examined. The predictive ability of a 
multivariate score was also limited, and was insufficient for 
use in clinical practice without disadvantaging large numbers 
(shown in Table 5 in the supplementary file).
Perhaps unexpectedly, diabetes duration, and fasting in-
sulin and C-peptide concentrations did not emerge as signifi-
cant predictors of remission, probably because DiRECT only 
included participants within 6 years of diagnosis, although, 
a modest benefit for shorter disease duration was observed 
in a subgroup of participants reported separately.14Previous 
studies found that diabetes duration >6 years does impede re-
mission12,13 and shorter history of type 2 diabetes and higher 
C-peptide levels are consistent predictors of remission after 
bariatric surgery.14 Remissions were less likely for partici-
pants with elevated triglyceride and GGT concentrations: 
both are associated with non-alcoholic fatty liver disease,15 
commonly co-existing with type 2 diabetes, and are likely to 
reflect more extensive hepatic damage. People with a history 
of alcohol misuse were excluded from DiRECT, but we can-
not exclude additional effects from alcohol. Older age and 
higher blood pressure both emerged as modest predictors of 
F I G U R E  2  a) Predictions of remission at 24 months from baseline characteristics and from weight losses and attendance; b) Predictions of 
remission at 24 months: the estimated effect of weight loss; c) Predictions of remission at 24 months: effects independent of weight loss. The IMD 
reference is quintile 5 (i.e. the odds ratios shown are in relation to quintile 5)
Age (per 1 year)
Sex (female vs male)
IMD
Duration of diabetes (per 1 year)
SBP (per 10 mmHg)
HbA1c (per 5 mmol/mol)
HbA1c (per 1 %)
Insulin (per 10 uu/ml)
Triglycerides (per 1 mmol / l)
Gamma−glutamyl transferase (per 10 u/l)
C−peptide (per 1 ng/ml)
No. of antidiabetes medications (per 1 medication)
Metformin and
Gliclazide
No. of antihypertensives (per 1 medication)
Antidepressants
EQ−5D 100−point VAS (per 10 points)





EQ−5D anxiety and depression*
Binge eating score (per 1 point)
Weight loss at week 4 (per 1 kg)
Weight loss at week 4 (per 1 %)
Weight loss at week 8 (per 1 kg)
Weight loss at week 8 (per 1 %)
No. of treatment visits up to week 8 (per 1 visit)
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remission, associations which are counter-intuitive and re-
quire confirmation in future studies. There are some parallels 
between these results and data from the Look AHEAD trial, 
which reported 12% remissions with a mean 8 kg weight-
loss at 12 months, as a post hoc finding in participants with 
substantially longer-standing diabetes than in DiRECT. 
Remissions were more frequent among participants with 
greater weight loss at 12 months, shorter histories of diabe-
tes, lower baseline HbA1c, and in those not using insulin or 
taking anti-hypertensive drugs. Although the DiRECT study 
excluded people treated with insulin, this is unlikely to have 
introduced any unusual heterogeneity or bias, because rela-
tively few people are on insulin therapy within 6 years of type 
2 diabetes diagnosis.
There was a weak relationship between remission and the 
deprivation variable when considered as a whole, and our 
findings imply that people living in more socially deprived 
areas were less likely to achieve remission (Figures 1 and 2). 
This effect may have been related to other factors, such as 
lower quality of life, which was associated with higher depri-
vation and non-remission. These factors may warrant investi-
gation in future studies.
Weight loss is by far the most potent predictor of remis-
sion, which raises questions regarding predictors of weight 
loss, and also weight loss maintenance. Success or failure 
in losing and maintaining weight is influenced by inter-
acting biological, behavioural and environmental factors, 
and identifying reliable predictors in previous studies has 
proved difficult.16,17 Although it is beyond the scope of the 
present study to include a detailed investigation of weight 
loss predictors, the predictors of remission which were 
explained by weight change must themselves be predic-
tors of weight loss and maintenance. For example, higher 
anxiety/depression scores and antidepressant drug usage 
predicted poorer weight loss and therefore worse remis-
sion outcomes. Many antidepressant medications are obe-
sogenic,18 and persisting negative mood states are likely 
to interfere with adhering to diet and lifestyle recommen-
dations for weight loss maintenance.19 More remissions 
at 24 months in men was also explained principally by 
greater weight loss. The greater (absolute) weight loss in 
men was expected, since the fixed-energy diet prescribed 
during the initial weight loss period created a greater en-
ergy deficit in males, but higher percentage weight loss 
observed at both 12 and 24 months suggests that, in this 
context, men are particularly capable of adhering to a re-
strictive, low-calorie intervention. Men exhibit earlier 
and greater ectopic fat accumulation, whereas women 
Age (per 1 year)
Sex (female vs male)
IMD
Duration of diabetes (per 1 year)
SBP (per 10 mmHg)
HbA1c (per 5 mmol/mol)
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Antidepressants
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have larger stores of safer subcutaneous fat.20 Given their 
greater initial intra-abdominal fat stores, men are likely to 
have mobilized more visceral and less subcutaneous fat 
than women, contributing to greater improvements in in-
sulin sensitivity. Although fewer men than women tend 
to enrol onto weight management programmes,21 59% en-
rolled into DiRECT (with 56% in the intervention arm), 
suggesting that men were motivated by the potential of 
remission, discontinuing medications and overall health 
improvement. Frequency of professional contacts in clin-
ical weight management trials is a consistent predictor of 
programme adherence and weight loss and maintenance.16 
Whether attendance predicts weight loss/remission, the 
reverse, or both relationships, is unclear. Reverse causal-
ity may play a part since individuals regaining the most 
weight, and thus at greatest risk of remission relapse, are 
less likely to attend programme appointments, whereas 
success enhances motivation and promotes engagement.
It is notable that weight loss achieved in the early weeks 
of treatment (by 4 weeks) was associated with remission 
status at 12 and 24 months. This confirms that those los-
ing weight most rapidly tend to achieve better long-term 
outcomes.22 Early weight loss on a low-calorie diet is a 
clear marker of intervention acceptability and adherence, 
such that early ‘stopping rules’ could be proposed, to ex-
clude those who fail to achieve pre-specified early weight 
loss targets, however, in practice, we found that many who 
failed to achieve early weight loss withdrew from treat-
ment of their own accord, and some others still go on to 
be successful. Based on the DiRECT results, withdrawing 
the intervention from people who did not have good early 
weight loss would deny effective treatment to a significant 
minority who benefit from continued support and go on to 
achieve remissions at 12 and 24 months.
Durability of remission is dependent on weight loss main-
tenance, with remission relapsers regaining more weight 
between 12 and 24 months compared to those remaining in 
remission. In DiRECT participants achieving remission but 
subsequently relapsing, weight regain was strongly associ-
ated with re-accumulation of ectopic fat within the liver and 
pancreas.23 These findings are consistent with the view that 
both onset, and remission, of type 2 diabetes is determined 
by exceeding, or getting below, a ‘personal fat threshold’ 
within the liver and pancreas.24 There is a common belief 
that complete weight regain following diet-induced weight 
loss is inevitable, because of physiological adaptations25 and 
environmental influences26 opposing long-term weight loss 
maintenance; however, in DiRECT, a mean weight loss of 
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Triglycerides (per 1 mmol / l)
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11.4 kg (>10% body weight) in those achieving remission 
(n=53) at 2 years adds to the evidence that failure is not 
inevitable.27,28
While DiRECT offers a unique opportunity to assess 
potential clinical and demographic predictors of remission 
of type 2 diabetes, with a relatively large and complete da-
tabase of robust measurements, an even larger sample size 
would have provided further assurances with regard to the 
conclusions of our analyses. The study was conducted in 
people with a relatively short duration diabetes, and pre-
dominantly in white Europeans. More evidence is needed 
to establish the likelihood of remission with similar weight 
losses for people with longer disease durations, including 
those treated with insulin, and in people of other ethnici-
ties, although in a study similar to DiRECT, even higher 
remission rates were documented in a younger population 
from the Middle East/North Africa with shorter average 
(<2 years) duration of diabetes.29
In conclusion, remissions were frequent across all vari-
ables examined. The strongest predictors were greater 
weight loss and being prescribed fewer antidiabetes medi-
cations at baseline, whilst disease duration, fasting insulin 
and C-peptide did not influence likelihood of remission. 
Men were more successful at sustaining remission and 
higher weight losses over time, and appear well suited to 
this intervention. People with anxiety and/or depression 
were less successful and may benefit from additional sup-
port in weight management interventions. Other predictors 
of type 2 diabetes remission were modest, were largely ex-
plained by greater weight loss, and none were sufficient 
to identify people for whom remission is not a worthwhile 
target. These findings provide reliable and reassuring evi-
dence to clinicians, healthcare planners and people target-
ing type 2 diabetes remission.
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